Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).
HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).
The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.
This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.
The FDA chose HERNEXEOS for the CNPV program.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Formation Bio acquires worldwide rights to FHND5032 from CTFH
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
Almirall receives China approval for Seysara to treat moderate-to-severe acne